149 related articles for article (PubMed ID: 29847952)
1. An NAD(P)H:Quinone Oxidoreductase 1 Responsive and Self-Immolative Prodrug of 5-Fluorouracil for Safe and Effective Cancer Therapy.
Zhang X; Li X; Li Z; Wu X; Wu Y; You Q; Zhang X
Org Lett; 2018 Jun; 20(12):3635-3638. PubMed ID: 29847952
[TBL] [Abstract][Full Text] [Related]
2. Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system.
Volpato M; Abou-Zeid N; Tanner RW; Glassbrook LT; Taylor J; Stratford I; Loadman PM; Jaffar M; Phillips RM
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3122-30. PubMed ID: 18089707
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.
Zhu H; Lu L; Zhu W; Tan Y; Duan Y; Liu J; Ye W; Zhu Z; Xu J; Xu S
Eur J Med Chem; 2022 Oct; 240():114575. PubMed ID: 35803175
[TBL] [Abstract][Full Text] [Related]
4. Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment.
Yang X; Duan J; Wu L
Future Med Chem; 2022 Mar; 14(5):363-383. PubMed ID: 35102756
[TBL] [Abstract][Full Text] [Related]
5. A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy.
Liu P; Xu J; Yan D; Zhang P; Zeng F; Li B; Wu S
Chem Commun (Camb); 2015 Jun; 51(46):9567-70. PubMed ID: 25971544
[TBL] [Abstract][Full Text] [Related]
6. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
Zhang K; Chen D; Ma K; Wu X; Hao H; Jiang S
J Med Chem; 2018 Aug; 61(16):6983-7003. PubMed ID: 29712428
[TBL] [Abstract][Full Text] [Related]
7. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
Gustafson DL; Beall HD; Bolton EM; Ross D; Waldren CA
Mol Pharmacol; 1996 Oct; 50(4):728-35. PubMed ID: 8863816
[TBL] [Abstract][Full Text] [Related]
8. Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.
Mendoza MF; Hollabaugh NM; Hettiarachchi SU; McCarley RL
Biochemistry; 2012 Oct; 51(40):8014-26. PubMed ID: 22989153
[TBL] [Abstract][Full Text] [Related]
9. NAD(P)H:Quinone Acceptor Oxidoreductase 1 (NQO1) Activatable Salicylamide H
Roy NJ; Save SN; Sharma VK; Abraham B; Kuttanamkuzhi A; Sharma S; Lahiri M; Talukdar P
Chemistry; 2023 Sep; 29(51):e202301412. PubMed ID: 37345998
[TBL] [Abstract][Full Text] [Related]
10. Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).
Fryatt T; Pettersson HI; Gardipee WT; Bray KC; Green SJ; Slawin AM; Beall HD; Moody CJ
Bioorg Med Chem; 2004 Apr; 12(7):1667-87. PubMed ID: 15028260
[TBL] [Abstract][Full Text] [Related]
11. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
12. Self-immolative polyprodrug-based tumor-specific cascade amplificated drug release nanosystem for orchestrated synergistic cancer therapy.
Wang K; Xiao X; Liu Y; Zong Q; Tu Y; Yuan Y
Biomaterials; 2022 Oct; 289():121803. PubMed ID: 36150300
[TBL] [Abstract][Full Text] [Related]
13. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
[TBL] [Abstract][Full Text] [Related]
14. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Siegel D; Yan C; Ross D
Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
[TBL] [Abstract][Full Text] [Related]
15. NQO1-selective activated prodrugs of combretastatin A-4: Synthesis and biological evaluation.
Zhang C; Qu Y; Ma X; Li M; Li S; Li Y; Wu L
Bioorg Chem; 2020 Oct; 103():104200. PubMed ID: 32890998
[TBL] [Abstract][Full Text] [Related]
16. Benzimidazole- and benzothiazole-quinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1.
Newsome JJ; Colucci MA; Hassani M; Beall HD; Moody CJ
Org Biomol Chem; 2007 Nov; 5(22):3665-73. PubMed ID: 17971996
[TBL] [Abstract][Full Text] [Related]
17. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
Knox RJ; Jenkins TC; Hobbs SM; Chen S; Melton RG; Burke PJ
Cancer Res; 2000 Aug; 60(15):4179-86. PubMed ID: 10945627
[TBL] [Abstract][Full Text] [Related]
18. Self-Strengthened Oxidation-Responsive Bioactivating Prodrug Nanosystem with Sequential and Synergistically Facilitated Drug Release for Treatment of Breast Cancer.
Wang K; Yang B; Ye H; Zhang X; Song H; Wang X; Li N; Wei L; Wang Y; Zhang H; Kan Q; He Z; Wang D; Sun J
ACS Appl Mater Interfaces; 2019 May; 11(21):18914-18922. PubMed ID: 31055911
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
[TBL] [Abstract][Full Text] [Related]
20. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
